CClinicalTrials.gg
RecruitingNCT07229508TRACKUpdated Nov 17, 2025

Developmental Trajectories of Reinforcer Pathology and Childhood Obesity

An observational study in Pediatric Obesity, sponsored by State University of New York at Buffalo. Recruiting at 1 site in United States. Open to participants aged 8 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by State University of New York at Buffalo · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
8 Years to 11 Years
Sex
All
01

Study summary

The goal of this observational study is to understand how children's food preferences, physical activity, and decision-making change over time and how these behaviors relate to body weight and overall health.

Read the detailed description

A cohort sequential design will be used to track 2 cohorts of children aged 8.5-9 years 11 months, and 10.5-11 years 11 months over a 3 year period to understand how the development of food and activity reinforcement and delay discounting could lead to the development of childhood obesity in children aged 9-14.

02

Conditions studied

  • Pediatric Obesity

Browse trials for

Keywords

  • Reinforcer Pathology Theory
  • Reinforcing Value
  • Delay Discounting
03

In context

Pediatric Obesity

1,117 studies on the registry are indexed under Pediatric Obesity; 189 are open to participants now.

This study's planned enrollment of 250 is above the median of 200 across 231 observational studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

State University of New York at Buffalo is the lead sponsor of 287 studies on the registry; 65 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Male and female children of varying racial/ethnic backgrounds, SES backgrounds, and varying body compositions

Inclusion criteria

  • Male and female children
  • Black, Indigenous, and People of Color (BIPOC) or Hispanic families
  • Children from low SES families (as defined by household education, eligibility for government assistance)
  • Children in overweight/obese category (defined by range in each cohort)

Exclusion criteria

Exclusion Criteria:

  • Medical causes for obesity
  • Stature below the 5th percentile
  • Physical activity restrictions
  • Psychopathology
  • Medication use that affects activity or appetite
  • Children that spend less than 65% of their time in participating parent's household
  • BMI percentile criteria
  • Liking of study foods and activities
  • Dietary restrictions and food allergies
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aged 8.5-9

    Children that are enrolled when they are 8.5- 9 years, 11 months of age

  • Aged 10.5-11

    Children that are enrolled when they are 10.5-11 years, 11 months age

06

What researchers measure

Primary outcomes

  1. zBMI

    Height and weight will be measured to determine zBMI using the CDC extended BMI-for-age growth charts. First, height (m) and weight (kg) will be used to calculate BMI (kg/m\^2), then, using the CDC extended BMI-for-age growth charts, a zBMI score will be determined based on the charts.

    Time frame: 0, 12, 24 and 36 months

  2. body fat

    Body fat (% of body weight) will be measured using the Tanita BF-400 Total Body Analyzer.

    Time frame: 0, 12, 24 and 36 months

  3. percent change over the overweight BMI

    Height and weight will be measured to calculate changes in overweight status of children. Change in percent overweight from 0, 12, 24, 36 months. First, height and weight will be used to calculate BMI (kg/m\^2), then CDC extended growth charts will be used to determine BMI percentile. Percent overweight is calculated as ((childBMI percentile - 85th BMI percentile)/(85th BMI percentile)) x 100. Percent over the age- and sex- specific 85th BMI percentile for children will be used.

    Time frame: 0, 12, 24 and 36 months

07

Study locations

1 of 1 sites recruiting
  • State University of New York at Buffalo
    Buffalo, New York 14214, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07229508
Lead sponsor
State University of New York at Buffalo
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Leonard Epstein (Principal Investigator, State University of New York at Buffalo) — Principal investigator
First posted
Nov 17, 2025
Start date
Nov 6, 2025
Primary completion
Oct 1, 2030 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Nov 17, 2025

Study contacts

Mary J Hite, BA
Contact
maryjohi@buffalo.edu
7168292261
Katelyn Carr, PhD
Contact
kcarr@buffalo.edu
7168296814
Leonard H Epstein, PhD
principal investigator · SUNY-University at Buffalo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion